View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 4, 2011

DARPA funds Aethlon to develop sepsis therapeutic device

Defense Advanced Research Projects Agency (DARPA) has awarded a $6.8m contract to Aethlon Medical to develop a therapeutic device to reduce the incidence of sepsis.

Defense Advanced Research Projects Agency (DARPA) has awarded a $6.8m contract to Aethlon Medical to develop a therapeutic device to reduce the incidence of sepsis.

The contract programme will leverage the Aethlon ADAPT system as a core technology component underlying an extracorporeal blood purification device which selectively clears multiple sepsis-enabling particles from circulation to promote recovery and prevent sepsis.

The Aethlon ADAPT system is an adaptive dialysis-like affinity platform technology that selectively targets the clearance of harmful agents from the circulatory system without the loss of essential blood components.

The ADAPT system, which is being developed under DARPA’s dialysis like therapeutics (DLT) programme, is expected to decrease the morbidity and mortality of sepsis.

Aethlon Medical chairman and CEO Jim Joyce said the award reinforces the expansive capabilities of ADAPT system, increases the breadth of their product pipeline and transitions them from a development-stage to revenue-stage organisation.

 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management